Download PDF
Gastroenterologie up2date 2013; 09(03): 195-208
DOI: 10.1055/s-0033-1344515
Leber/Galle/Pankreas
© Georg Thieme Verlag KG Stuttgart · New York

Medikamentös induzierte Leberschädigung

Hans Christian Spangenberg
Further Information

Publication History

Publication Date:
01 September 2013 (online)

Also available at
    Permissions and Reprints All articles of this category
Kernaussagen

Epidemiologie und Pathogenese

  • Die Inzidenz der arzneimitteltoxischen Hepatopathie liegt bei etwa 14 – 20 pro 100000 Einwohner.

  • Die arzneimitteltoxischen Hepatopathien werden in den idiosynkratischen, nicht vorhersagbaren und den intrinsischen, vorhersagbaren Typ unterteilt.

  • Zahlreiche nicht genetische und genetische Risikofaktoren für die Pathogenese des idiosynkratischen Typs sind näher charakterisiert.

Diagnostik und Therapie

  • Die arzneimitteltoxische Hepatopathie kann nahezu jede Form einer akuten und chronischen Lebererkrankung – sowohl im klinischen Erscheinungsbild als auch laborchemisch und histologisch – imitieren.

  • Der Schlüssel zur Diagnosestellung ist eine ausführliche, akkurate Anamnese. Die am häufigsten mit medikamentös-toxischer Hepatopathie in Verbindung stehenden Substanzgruppen sind Antibiotika, verschiedene Analgetika und nichtsteroidale Antirheumatika.

  • Neben den klassischen Medikamenten muss auch der Einnahme pflanzlicher Präparate und naturheilkundlicher Medikamente Beachtung geschenkt werden.

  • Im Allgemeinen ist die Prognose der arzneimitteltoxischen Hepatopathie als gut anzusehen. In den meisten Fällen ist eine Restitutio ad integrum zu erwarten und die Gefahr der Entwicklung einer klinisch relevanten chronischen Lebererkrankung als eher gering zu bewerten.

  • Die wohl wichtigsten therapeutischen Maßnahmen sind die frühzeitige Identifikation und das alsbaldige Absetzen der auslösenden Substanz.

 

  • Literatur

  • 1 Sgro C, Clinard F, Ouazir K et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36: 451-455
    CrossrefPubMedGoogle Scholar
  • 2 Björnsson ES, Bergmann OM, Björnsson HK et al. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-1425
    CrossrefPubMedGoogle Scholar
  • 3 De Valle MB, Av Klinteberg V, Alem N et al. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006; 24: 1187-1195
    CrossrefPubMedGoogle Scholar
  • 4 Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007; 11: 477-505
    CrossrefPubMedGoogle Scholar
  • 5 Larrey D. Drug-induced liver diseases. J Hepatol 2000; 32: 77-88
    PubMedGoogle Scholar
  • 6 Ostapowicz G, Fontana RJ, Schiodt FV et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-954
    CrossrefPubMedGoogle Scholar
  • 7 Fountain FF, Tolley E, Chrisman CR et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005; 128: 116-123
    CrossrefPubMedGoogle Scholar
  • 8 Lucena MI, Andrade RJ, Fernandez MC et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 2006; 44: 850-856
    CrossrefPubMedGoogle Scholar
  • 9 Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis 2009; 29: 337-347
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Lucena MI, Andrade RJ, Kaplowitz N et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009; 49: 2001-2009
    CrossrefPubMedGoogle Scholar
  • 11 Russo MW, Galanko JA, Shrestha R et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004; 10: 1018-1023
    CrossrefPubMedGoogle Scholar
  • 12 Lammert C, Einarsson S, Saha C et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008; 47: 2003-2009
    CrossrefPubMedGoogle Scholar
  • 13 Lammert C, Bjornsson E, Niklasson A et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010; 51: 615-620
    CrossrefPubMedGoogle Scholar
  • 14 Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99: 465-471
    CrossrefPubMedGoogle Scholar
  • 15 Schmidt LE, Dalhoff K, Poulsen HE. Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity. Hepatology 2002; 35: 876-882
    CrossrefPubMedGoogle Scholar
  • 16 Lewis JH. The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert Opin Drug Saf 2002; 1: 159-172
    CrossrefPubMedGoogle Scholar
  • 17 Russo MW, Watkins PB. Are patients with elevated liver tests at increased risk of drug-induced liver injury?. Gastroenterology 2004; 126: 1477-1480
    CrossrefPubMedGoogle Scholar
  • 18 Andrade RJ, Robles M, Ulzurrun E et al. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics 2009; 10: 1467-1487
    CrossrefPubMedGoogle Scholar
  • 19 Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Semin Liver Dis 2009; 29: 400-411
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Wilke RA, Lin DW, Roden DM et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007; 6: 904-916
    CrossrefPubMedGoogle Scholar
  • 21 Daly AK, Donaldson PT, Bhatnagar P. DILIGEN Study; International SAE Consortium et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816-819
    CrossrefPubMedGoogle Scholar
  • 22 Larrey D, Pageaux GP. Genetic predisposition to drug-induced hepatotoxicity. J Hepatol 1997; 26: 12-21
    CrossrefPubMedGoogle Scholar
  • 23 Berson A, Freneaux E, Larrey D et al. Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. J Hepatol 1994; 20: 336-342
    CrossrefPubMedGoogle Scholar
  • 24 Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22: 145-155
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Lee WM, Larrey D, Olsson R et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005; 28: 351-370
    CrossrefPubMedGoogle Scholar
  • 26 Kleiner DE. The pathology of drug-induced liver injury. Semin Liver Dis 2009; 29: 364-372
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Hayashi PH. Causality assessment in drug-induced liver injury. Semin Liver Dis 2009; 29: 348-356
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Suzuki A, Andrade RJ, Bjornsson E et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf 2010; 33: 503-522
    CrossrefPubMedGoogle Scholar
  • 29 Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol 2008; 14: 6774-6785
    CrossrefPubMedGoogle Scholar
  • 30 Strader DB, Bacon BR, Lindsay KL et al. Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol 2002; 97: 2391-2397
    CrossrefPubMedGoogle Scholar
  • 31 Suk TK, Kim DJ. Drug-induced liver injury: present and future. Clin Mol Hepatol 2012; 18: 249-257
    CrossrefPubMedGoogle Scholar
  • 32 Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42: 481-489
    CrossrefPubMedGoogle Scholar
  • 33 Andrade RJ, Lucena MI, Fernandez MC et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521
    CrossrefPubMedGoogle Scholar
  • 34 Chun LJ, Tong MJ, Busuttil RW et al. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol 2009; 43: 342-349
    CrossrefPubMedGoogle Scholar
  • 35 Andrade RJ, Lucena MI, Kaplowitz N et al. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology 2006; 44: 1581-1588
    CrossrefPubMedGoogle Scholar
  • 36 Bjornsson E, Kalaitzakis E, Av Klinteberg V et al. Long-term follow-up of patients with mild to moderate drug-induced liver injury. Aliment Pharmacol Ther 2007; 26: 79-85
    CrossrefPubMedGoogle Scholar
  • 37 Bohan TP, Helton E, McDonald I et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001; 56: 1405-1409
    CrossrefPubMedGoogle Scholar
  • 38 Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005; 41: 1179-1197
    CrossrefPubMedGoogle Scholar
  • 39 Lee WM, Hynan LS, Rossaro L et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009; 137: 856-864, 864 e1
    CrossrefPubMedGoogle Scholar
  • 40 Wree A, Dechêne A, Herzer K et al. Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury. Digestion 2011; 84: 54-59
    CrossrefPubMedGoogle Scholar